Phase II Study of Mosunetuzumab, Polatuzumab Vedotin, Tafasitamab, and Lenalidomide for Relapsed B-cell Non-Hodgkin Lymphoma

What this Trial Is About

Researchers are evaluating the combination of four drugsmosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomidein adults with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma DLBCL, types of B-cell non-Hodgkin lymphoma NHL. This phase II trial aims to determine the safety of this drug combination and measure how well it helps control the disease by assessing response rates and survival outcomes. The study will also explore changes in immune cells and the tumor environment after treatment. The trial includes a safety run-in phase where the tolerable doses of the four drugs are tested. Afterward, participants receive the established dose level in the dose expansion phase. Mosunetuzumab, polatuzumab vedotin, and tafasitamab are given intravenously through a vein, while lenalidomide is taken orally. The study groups involve participants receiving these drugs in combination as experimental treatment. The treatment schedule and dosing are based on findings from the safety testing phase. Participants will be closely monitored during the study with assessments to track treatment response and safety. The primary outcome measured is the best overall response rate over approximately one year. Researchers will evaluate effects on disease control and survival, as well as immune system changes. Participants must agree to various safety measures, including contraception and blood tests, and will be followed through the study duration until completion around 2027.

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL